secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2024-06-26T23:59:59+00:00
Accession:  0000950170-24-077636
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint announces Phase 3 plans for DURAVYU in wet AMD; positive Phase 2 data
------------------------------------------------------------------------------

- Phase 3 LUGANO and LUCIA trials to enroll ~400 patients each; 2.7mg DURAVYU vs aflibercept; one-year endpoint.
- Phase 2 DAVIO 2 data: favorable safety, BCVA nearly identical to aflibercept at 12 months post single injection.
- After single DURAVYU dose, ~50% of eyes were supplement-free at 12 months vs 22% for aflibercept control.
- Phase 2 VERONA trial in DME fully enrolled with 27 patients; no drug-related SAEs reported.
- First patient dosing in Phase 3 LUGANO expected 2H 2024; FDA alignment on non-inferiority design with redosing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024077636/0000950170-24-077636-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024077636/eypt-20240626.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-077636

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer